Gilenya Side Effects Being Reviewed by European, U.S. Regulators

Staff Writers

Add Your Comments

European regulators have placed Gilenya, Novartis’s multiple-sclerosis drug, under review due to potential links to heart problems.

The European Medicines Agency (EMA) announced on Friday that it has begun a review of Gilenya side effects and benefits after reports that a patient in the U.S. died of heart problems less than 24 hours after taking the drug.

Other patients have reported heart problems from Gilenya as well, and concerns have already sparked a Gilenya investigation in the United States by the FDA.

Do You Know about…

SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS

Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Do You Know About…

SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS

Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Gilenya (fingolimod) is a Novartis drug approved in 2010 as an oral treatment for relapsing forms of MS in adults. It is used to reduce how often flare-ups occur and to delay the onset of physical disability caused by MS.

While the EMA conducts its review, it’s Committee for Medicinal Products for Human Use (CHMP) has told doctors to more closely monitor patients after giving them their first dose of Gilenya. CHMP recommends that doctors conduct electrocardiogram (ECG) monitoring before treatment and continue monitoring for the six hours after the patient takes the first dose.

The risk of some heart irregularities after the first dose were a concern before the drug was approved. Known side effects of Gilenya include a decrease in heart rate and/or atrioventricular conduction after the first dose. It is also known to increase the risks of developing heart blocks or bradycardia when taken with some other drugs, including beta blockers and calcium channel blockers.

In the United States, the FDA is recommending that patients be informed Gilenya may cause serious side effects, such as a low heart rate, that can cause symptoms including dizziness, fatigue and palpitations after the first dose. The heart rate typically returns to normal within the first month of taking the drug. Patients should contact their health care provider if these symptoms occur.

The CHMP anticipates that the review into the potential Gilenya side effects will be complete by March.

Tags: Gilenya, Heart Failure, Multiple Sclerosis, Novartis

More Lawsuit Stories

1 Comments

Lorraine
I suffered a gilenya side effect in December, 2011. I suffered from PRES posterior reversible encephalopathy syndrome. I had high BP and seizures.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Nearly 4,000 Women Pursuing a Depo-Provera Lawsuit After Developing Brain Tumors
More than 3,300 women have filed Depo-Provera lawsuits in federal court, with several hundred more also pending in state courts in New York and Delaware, according to a recent status report.
Suboxone Film Lawsuit Filed by 46 Users Alleges Drug Makers Ignored Years of Mounting Dental Injury Reports
A group of 46 people say they suffered dental injuries and tooth damage due to the side effects of Suboxone film strips, which eroded their tooth enamel.
MDL Trial for Covidien Hernia Mesh Lawsuit Remains On Track for July 2026
A federal judge has agreed to delay a motion for summary judgment in the first Covidien hernia mesh bellwether trial, after the parties agreed that the outcome would not affect the upcoming trial date.